Conviction: Medium-High
Status: Watching — RSI 32.2 approaching neutral, price recovering +0.3% today, SMA gap tightening
Quick Snapshot
| Signal |
Reading |
| Overall |
🟡 RSI 32.2 — recovered from extreme 5.5 on 02/16 and 19.2 on 02/22. Price $515.03, +0.3% today, +2.7% this week. -17.8% in 30 days. SMA declining toward price. |
| Moat |
Wide (lab equipment, reagents, instruments monopoly) |
| Key insight |
TMO continues its RSI recovery — from extreme 5.5 → 19.2 → 32.2. Price is showing steady improvement (+2.7% this week). SMA20 ($535.17) declining fast. The life sciences picks-and-shovels thesis is unchanged. Insider selling ($323.3M) remains the key risk. RSI approaching the oversold/neutral boundary — next reading above 35 would signal a clear technical recovery. |
Action Matrix
| Action |
Level |
Why |
| Current |
✅ Buy |
RSI 32.2 — recovering from extreme. Wide moat. Price recovering with RSI. |
| Entry Zone |
$490 - $525 |
Current $515.03 — IN ZONE |
| Stop-Loss |
$440 (-15%) |
Below multi-year support |
| Target |
$650 (+26%) |
Recovery toward SMA and prior levels |
Price Data
| Stock |
Price |
1D |
7D |
30D |
3M |
52wkHi |
RSI |
Status |
Action |
| TMO |
$515.03 |
+0.3% |
+2.7% |
-17.8% |
— |
-17.8% |
32 |
🟡 Approaching Neutral |
✅ Buy |
Price vs Last Deep Dive (02/22)
| Metric |
02/22 |
02/26 |
Change |
| Price |
$510.93 |
$515.03 |
+$4.10 (+0.8%) |
| RSI |
19.2 |
32.2 |
+13.0 (continued recovery) |
| SMA20 |
$556.36 |
$535.17 |
-$21.19 (SMA declining fast) |
| vs SMA |
-8.2% |
-3.8% |
Gap narrowing rapidly |
Update from 02/22: TMO's RSI recovery continues — from extreme 5.5 (02/16) to 19.2 (02/22) to 32.2 now. Price has also improved modestly from $510.93 to $515.03 (+0.8%). This week's +2.7% is encouraging. The SMA20 has dropped sharply from $556 to $535, and the price gap has narrowed from -8.2% to -3.8%. TMO is in a clear technical recovery pattern: RSI recovering in steps, SMA declining to meet price, gap narrowing. At RSI 32.2, it's approaching the oversold/neutral boundary. The Buy action is maintained — still in the entry zone.
Company Overview
One-Liner
Thermo Fisher Scientific is the world's largest life sciences company, providing analytical instruments, equipment, reagents, and services to every lab and pharma company globally.
Business Model
| Question |
Answer |
| What they sell |
Lab instruments/equipment, scientific reagents, specialty chemicals, CRO/bioprocessing services |
| Who pays |
Pharma/biotech (50%), hospitals/diagnostic labs (20%), academic/government (20%), industrial (10%) |
| Revenue model |
Equipment sales (one-time), consumables/reagents (recurring), service contracts, bioproduction (recurring) |
| How sticky |
Very high — scientific instruments require calibration, reagents are qualified per protocol, switching risks experiment reproducibility |
Key Segments
| Segment |
Revenue % |
Growth |
Notes |
| Life Sciences Solutions |
~35% |
+8% YoY |
Reagents, bioprocessing, gene editing tools |
| Analytical Instruments |
~25% |
+6% YoY |
Mass spec, chromatography, electron microscopy |
| Specialty Diagnostics |
~20% |
+5% YoY |
Clinical diagnostic kits, allergy testing |
| Laboratory Products & Biopharma Services |
~20% |
+4% YoY |
Lab supplies, CRO services (PPD) |
Competitive Analysis
Competitive Moat
| Moat Type |
Present? |
Evidence |
| Switching costs |
🟢 |
Scientific protocols lock in specific instruments/reagents; revalidation cost is prohibitive |
| Intangible assets |
🟢 |
Thermo, Fisher Scientific, Life Technologies brand trust in research community |
| Network effects |
🟡 |
Scientific literature references specific TMO instruments/reagents |
| Cost advantages |
🟢 |
$45B+ revenue generates unmatched supply chain scale |
| Efficient scale |
🟢 |
Only company covering full lab workflow from sample prep to analysis |
Moat Width: Wide
Moat Trend: Stable — life sciences R&D spend is structural, not cyclical long-term
TMO vs IQV (Comparison)
Both are life sciences compounders — but diverging in recovery:
| Metric |
TMO |
IQV |
| RSI |
32.2 |
17.4 |
| 30D |
-17.8% |
-32.2% |
| Moat |
Wide |
Wide |
| Revenue |
$45B |
$16B |
| Insider Selling |
$323.3M |
-$39.8M |
| Recovery Signal |
RSI +13 pts this week |
RSI deteriorating |
Bull Case
Why This Could Work
- Essential life sciences infrastructure — Every hospital, pharma company, and lab needs TMO products. No substitution.
- Bioproduction secular tailwind — mRNA, cell therapy, gene editing all require TMO's bioprocessing equipment.
- RSI recovery 5.5 → 19.2 → 32.2 — Steady, sustained recovery pattern — most constructive in our coverage.
- Picks-and-shovels for pharma AI — AI drug discovery increases demand for analytical instruments.
- SMA gap narrowing from -8.2% → -3.8% — Convergence accelerating.
Upside Scenario
| If This Happens |
Stock Could |
| Bioproduction recovery + multiple normalization |
$650 (+26%) |
| Pharma R&D spending re-acceleration |
$700 (+36%) |
Bear Case
What Could Go Wrong
- Pharma R&D budget cuts — Largest customer segment cutting spending post-COVID boom.
- Insider selling $323.3M — Among highest in our universe alongside ISRG.
- China exposure — ~15% China revenue; geopolitical risk on analytical instruments.
- CRO competition — PPD segment (acquired 2021) faces IQVIA competition.
Thesis Killers
- Pharma top 10 companies announce R&D budget cuts exceeding 10%
- China bans TMO instrument imports
- Bioproduction demand collapses (mRNA era over)
Entry Strategy
Technical Levels
| Level |
Price |
Notes |
| Support 1 |
$490 |
Recent floor / entry zone bottom |
| Support 2 |
$440 |
Stop-loss; multi-year support |
| Resistance 1 |
$535.17 |
SMA20 — declining toward price |
| Resistance 2 |
$580 |
3-month prior range |
| 52-week high |
$626.62 |
In-window high |
| 52-week low |
~$460 |
(estimated) |
Entry Approach
| Strategy |
Details |
| Entry zone |
$490 - $525 |
| Starter |
2% of portfolio |
| Add |
RSI breaks above 35 with price above $520 |
| Full |
RSI > 40 + SMA20 convergence |
Research Log
| Date |
Update |
| 2026-02-16 |
Created deep dive. RSI 5.5 extreme (!). $504.82. -13% below SMA. Insider selling $323.3M. Action: Buy. |
| 2026-02-22 |
Price refresh. $510.93 (+1.2%). RSI 19.2 (from 5.5 — largest improvement in coverage: +13.7 pts). SMA gap narrowed from -13% to -8.2%. Still extreme oversold. Buy maintained. |
| 2026-02-26 |
Price continued recovery to $515.03 (+0.8%). RSI 19.2 → 32.2 (+13 pts — steady recovery). SMA gap narrowed from -8.2% → -3.8%. 7D +2.7%. Approaching oversold/neutral boundary. Buy maintained — near entry zone top. |
The Gold
Key Discoveries
| Discovery |
Implication |
| RSI 5.5 → 19.2 → 32.2 = steady stepwise recovery |
Most constructive recovery pattern in coverage; not a false bounce |
| SMA gap: -13% → -8.2% → -3.8% in 10 days |
SMA converging — price may reach SMA without a big price move |
| Price: $504 → $510 → $515 — steady upward |
Price recovering alongside RSI — both signals aligned |
| 7D +2.7% vs IQV 7D -8.4% |
TMO diverging positively from CRO peer IQV |
Open Questions
- What drove the RSI 5.5 extreme — was it forced selling/index rebalancing?
- Are the insider sales ($323.3M) on scheduled 10b5-1 plans?
- What is TMO's China revenue exposure and risk?
- When does TMO report next earnings?
- Why is TMO recovering while IQV continues to deteriorate? (Both life sciences, different dynamics)
Mistakes (Don't Repeat)
| Mistake |
Lesson |
| None yet |
Stepwise RSI recovery (5.5 → 19 → 32) is the cleanest buy signal pattern we track |
Sources
- Fundamentals figures: company-reported results (quarterly/annual filings) as available at the artifact date; predates the desk's EDGAR reconciliation gate — figures not re-verified after publication.